SCHEMBL4906407

SCHEMBL4906407

CC(=O)c1ncc2ccccc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.46
MAP4K4 O95819 1/20 0.43
CSNK1G2 P78368 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
MKNK2 Q9HBH9 1/20 0.43
MAP4K5 Q9Y4K4 1/20 0.43
KDM4E B2RXH2 5/20 0.42
HSP90AA1 P07900 1/20 0.42
HSP90AB1 P08238 1/20 0.42
CYP1A2 P05177 3/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MGAM O43451 2/20 0.41
HTR3A P46098 1/20 0.40
HRH4 Q9H3N8 1/20 0.40
PDE10A Q9Y233 1/20 0.40
GPR3 P46089 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31325746 1.00 MAP3K5 (0.46) MAP3K5MAP4K4CSNK1G2CLK4MKNK2
SCHEMBL5350724 0.82 MGAM (0.42) MAP3K5KDM4ECYP1A2MAPTSMN1; SMN2
SCHEMBL29427872 0.82 MGAM (0.50) MAP3K5KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL2337793 0.82 MGAM (0.50) MAP3K5KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL18622324 0.81 MAP3K5 (0.44) MAP3K5KDM4EHSP90AA1HSP90AB1CYP1A2
SCHEMBL422040 0.81 IKBKB (0.47) MAP3K5KDM4ECYP1A2MAPTSMN1; SMN2
SCHEMBL29668334 0.81 IKBKB (0.47) MAP3K5KDM4ECYP1A2MAPTSMN1; SMN2
SCHEMBL2005662 0.81 MGAM (0.41) MAP3K5KDM4ECYP1A2MAPTSMN1; SMN2
SCHEMBL16506805 0.81 RAB9A (0.41) MAP3K5KDM4ECYP1A2MAPTSMN1; SMN2
SCHEMBL18463840 0.81 CYP1A2 (0.40) MAP3K5MAP4K4CSNK1G2CLK4MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US claimed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US claimed
CN-119569661-B Preparation method of 2-acetylquinazoline-4 (3H) ketone compound 重庆医科大学 2025-10-17 CN disclosed
CN-119569661-A Preparation method of 2-acetylquinazoline-4 (3H) ketone compound 重庆医科大学 2025-03-07 CN disclosed
CN-119569661-A Preparation method of 2-acetylquinazoline-4 (3H) ketone compound 重庆医科大学 2025-03-07 CN disclosed
US-8227426-B2 Chiral complexes of ascorbic acid with natural antioxidant and anti-inflammatory ketones including aloe, citrus, ginger, and mango for skin and hair care ISLAND KINETICS INC. (US) 2012-07-24 US disclosed
US-20110059907-A1 Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care ISLAND KINETICS INC. (US) 2011-03-10 US disclosed
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles BIODERM RESEARCH (US) 2008-10-16 US disclosed
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US disclosed
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER INC. (US) 2007-07-12 US disclosed
US-7183293-B2 Ether derivatives useful as inhibitors of PDE4 isozymes PFIZER INC. (US) 2007-02-27 US disclosed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059907-A1 Chiral Complexes of Ascorbic Acid with Natural Antioxidant and Anti-Inflammatory Ketones Including Aloe, Citrus, Ginger, and Mango for Skin and Hair Care GLA, LPO, PLOD3 MAP3K5 1346/4885MAP4K4 1789/4885CSNK1G2 1566/4885
US-20070161681-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PDE4A, PDE4B, PDE4D MAP3K5 1875/4885MAP4K4 1042/4885CSNK1G2 1720/4885
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction PSMB1, PLOD3, CUTA MAP3K5 1395/4885MAP4K4 2255/4885CSNK1G2 1124/4885
US-20080255228-A1 Ascorbic Acid Complexes for Skin Care Including Treatment of Dark Skin & Wrinkles PROC, COL1A1, CUTA MAP3K5 1063/4885MAP4K4 1938/4885CSNK1G2 1428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.